HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: An extended virology study

AIDS

Volumn 13, Issue 1, 1999, Pages 57-65

  Nunn, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiviral therapy; HIV 1 RNA; Progression; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

AIDS RELATED COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

EID: 0033031661     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199901140-00008     Document Type: Article

References (14)

1. 1. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
2. 2. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
3. 3. Brun-Vezinet F, Boucher C, Loveday C, et al.: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997, 350:983-990.
4. 4. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD: Changes in plasma HIV RNA levels and CD4 lymphocyte counts predict both response to anti-retroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
5. 5. Vlahov D, Graham N, Hoover D, et al.: Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998, 279:35-40.
6. 6. O'Brien TR, Blattner WA, Waters D, et al.: Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-110.
7. 7. Welles SL, Jackson JB, Yen-Lieberman B, et al: Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis 1996, 174:696-703.
8. 8. Yerly S, Perneger TV, Hirschel B, et al.: A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. The Swiss Cohort Study. Arch Intern Med 1998, 158:247-252.
9. 9. Phillips AN, Eron JJ, Bartlett JA, et al.: HIV-1 RNA levels and the development of clinical disease. AIDS 1996, 10:859-865.
10. 10. Perdersen C, Katzenstein T, Nielsen C, Lundgren JD, Gerstoff J: Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:93-99.
11. 11. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
12. 12. van Gemen B, Kievits T, Nara P, et al.: Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 1993, 7 (suppl 2):S107-S110.
13. 13. Schuurman R, Descamps D, Weverling GJ, et al.: Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996, 34:3016-3022.
14. 14. Opravil M, DeMasi R, Hill A: Prediction of long term HIV RNA suppression during zidovudine/lamivudine treatment. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg (FL), June 1997 [abstract 60].